Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
09/28/2007
Trade Name:
Lamisil Oral Granules
Generic or Proper Name (*):
terbinafine
Indications Studied:
Tinea capitis
Therapeutic Category:
Antifungal, topical
Ages Studied:
3-12 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Double-Blind/Active Control/Parallel Group
No Patients:
747
No Centers:
74
No Countries:
7
BPCA(B), PREA(P):
B
Asian:
1
Black:
320
Other:
284
White:
142
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
Countries:
Canada(7), Colombia(9), Egypt(3), Peru(5), South Africa (2), US(44), Venezuela(4)
-
-